Based on the pooled efficacy and safety data of the phase 3 trial, dupilumab might be a strong treatment option among patients with eosinophilic esophagitis (EoE), Evan S. Dellon, MD, said during his abstract presentation at the 2022 ACG Annual Scientific Meeting and Postgraduate Course on October 24, in Charlotte, North Carolina.

Dr Dellon is a professor of medicine and an adjunct professor of epidemiology for Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine, Chapel Hill, North Carolina.

Presenting the abstract cited for the Outstanding Research Award in the Esophagus Category, Dr Dellon pooled the results from parts A and B of phase 3 LIBERTY-EoE-TREET. Through their research, Dr Dellon and colleagues demonstrated the clinical, symptomatic, histologic, and endoscopic benefits of dupilumab among patients with EoE.

The investigators randomly assigned dupilumab 300 mg (N=122) and placebo (N=118) to adult participants with EoE. From the data collected on all endpoints at the end of 24 weeks, the researchers observed superior results with dupilumab compared with placebo.

Patients treated with dupilumab reported higher peak eosinophil count ≤6/hpf (59.0% vs 5.9%), greater absolute mean change in dysphagia symptom questionnaire (-23.2 vs -12.7), greater percentage change in peak eosinophil count (-80.1% vs 1.5%), and more patients achieving < 15 eos/hpf (77.0% vs 7.6%). Dupilumab treatment also yielded superior results over placebo in achieving <15 eos/hpf (77.0% vs 7.6%), in changing histologic scoring system grade (0.82 vs 0. 62), and in changing the endoscopic reference score (–3.95 vs –0.41).

“The findings here are that the pooled efficacy and safety data for parts A and B of the phase 3 trial are consistent with the results of the individual parts of the study that were previously reported, and which led to the drug being approved for EoE,” he said. “Of note, the approved dose is 300mg weekly as a subcutaneous injection.”

Dupilumab is the only medication FDA-approved to treat EoE in the US.

—Priyam Vora

Reference:
Dellon E. Dupilumab improves clinical, symptomatic, histologic, and endoscopic aspects of EoE up to 24 weeks: pooled results from parts A and B of phase 3 LIBERTY-EoE-TREET. Oral paper presentation. Plenary session 1A – Esophagus. Presented at: ACG 2022 Annual scientific meeting and Postgraduate course. Charlotte, NC. October 24, 2022.